SDZ DJN 608 MONOTHERAPY COMPARED TO GLIBENCLAMIDE MONOTHERAPY B304 E

SDZ DJN 608 单一疗法与格列本脲单一疗法 B304 E 相比

• 批准号: 6263512
• 负责人: JANET MCGILL
• 金额: $ 2.44万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263512
• 关键词: clinical research; diabetes mellitus therapy; diet therapy; drug administration rate /duration; drug screening /evaluation; glycosylation; hemoglobin; human subject; human therapy evaluation; hypoglycemic agents; noninsulin dependent diabetes mellitus; sulfonylurea

Evaluate the effect of SDZ DJN 608 120mg and 60mg montherapy compared to glibenclamide monotherapy (10mg/day) on glycosylated hemoglobin (HbA) at 24 weeks of double-blind treatment in patients previously treated by diet an sulfonylureas.

评估SDZ DJN 608 120 mg和60 mg单药治疗与格列本脲单药(10 mg/d)治疗24周时对糖化血红蛋白(HBA)的影响，这些患者以前接受过饮食和磺脲类药物治疗。